Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1

Autor: C Cheneau, S Barthier, J Lemonnier, Fabrice Andre, C Dubot, L Teixeira, A Escande, T De La Motte Rouge, T Petit, L Arnould, Laurent Arnould, Suzette Delaloge, Jerome Lemonnier, A Marti, L Stefani, F Berger, C Levy, P Barthelemy, S Nguyen, M Gardner, A Lortholary, François-Clément Bidard, J Plaza, L Joly, Thibault de la Motte Rouge, F Andre, I Bièche, C Alleaume, R Sabatier, B Lucas, Ivan Bieche, O Derbel, L Venat-Bouvet, F Del Piano, Florian Clatot, Anne-Claire Hardy-Bessard, Frédérique Berger, Margaux Marce, Thomas Bachelot, Anne Pradines, Jean-Luc Canon, Sandrine Marques, M Achille, H Ammarguellat, O Arsene, T Bachelot, C Bernard-Marty, F-C Bidard, N Bonichon-Lamichhane, N Bonnin, R Bouaita, A Boudrant, V-A Brunel, C Chakiba, F Clatot, F Dalenc, A De Gramont, L Deiana, C Delbaldo, V Delecroix, H Desclos, V D'Hondt, N Dohollou, J-M Ferrero, C Foa, J-S Frenel, C Garnier Tixidre, D Genet, O Gisserot, M Gozy, C Greilsamer, J Grenier, F Guinet, A-C Hardy-Bessard, J-P Jacquin, E Lachaier, S Ladoire, A-P Laurenty, R Le Scodan, N Leduc, E Legouffe, C Levache, F Lorchel, N Marques, J Medioni, A Melis, D Mille, D Mollon, L Moreau, I Moullet, M-A Mouret-Reynier, A Najem, H Orfeuvre, J-F Paitel, B Pistilli, C Riedl, P Soulie, D Spaeth, F Trouboul, C Valmar, H Vegas, A Zannetti, FC Bidard, S Delaloge, A Pradines, JL Canon, S Marques

Publikováno v: BMJ Open, Vol 12, Iss 3 (2022)

Introduction The combination of a CDK4/6 inhibitor with an aromatase inhibitor (AI) has recently become the gold standard for AI-sensitive first line treatment of oestrogen receptor-positive (ER+) HER2-negative (HER2−) advanced breast cancer. Howev

Externí odkaz: https://doaj.org/article/8faf6bbc845f4ceeb90674dd08e198da

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

1320 Eribulin mesylate in metastatic breast cancer, a focus on safety and efficacy in elderly patients. Results from the EVHALAVEN multicentric retrospective cohort

Autor: A. Brunot, P. Soibinet, C. Lefeuvre-Plesse, Thierry Petit, A. Marquis, M. Campone, M.J. Paillard, C. Gourmelon, J. Martin-babau, Olivier Tredan, H. Desclos, Lionel Uwer, L. Campion, M. Robert, Anne Patsouris, C. Korenbaum, M. Som, A.L. Septans, Hugues Bourgeois, Xavier Pivot

Publikováno v: European Journal of Cancer. 51:S193-S194

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::1804945aaa256f1d297c252db3c74ef0
https://doi.org/10.1016/s0959-8049(16)30563-9

Long Term Persistent Alopecia and Suboptimal Hair Regrowth after Adjuvant Chemotherapy for Breast Cancer: Alert for an Emerging Side Effect: ALOPERS Observatory

Autor: V. Delecroix, S. Van Hulst, Frank Priou, Jean-Philippe Metges, Y. Raoul, Christian Riche, D. Berton-Rigault, Y. Hadjarab, J. Egreteau, Fabrice Denis, Philippe Deguiral, Sophie Abadie-Lacourtoisie, Marc Porneuf, Pierre Kerbrat, Hélène Simon, H. Desclos, R. Lamy, A-C. Hardy-Bessard, M. Combe, F. Grude, Hugues Bourgeois, C. El Khouri

Publikováno v: Cancer Research. 69:3174-3174

Background: Since 2003, through the impetus given by Pr Erick Gamelin and the Regional Health Agency in Western France (Bretagne, Pays de Loire), a network called OMIT (Drugs and Emerging Therapeutics Observatory) has been created, including the Brea

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bdc4c42eb4a3a96599e26f6684452e55
https://doi.org/10.1158/0008-5472.sabcs-09-3174

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.